United States · Investor

Longwood Fund

Last cheque observed Aug 2026; 53 cheques on record.

Email

Deploying nowNew fund $158M, Dec 2024VC firm

SeedSeries ASeries BAnalyticsBio TechnologyBiotechnology

Deploying now
67%of best year8cheques in 12 months, 53 on record
Since the last cheque79days00hrs00min00sec
Median round$60MCheque size, as they say$100K – $5.0MRounds led1 of 53Sole investor4 roundsExits2 from the portfolioMostly inUnited States, 89%
Pitch Longwood Fund

Longwood Fund highlights

  1. 01

    8 cheques in the last 12 months

  2. 02

    Mostly Series A and Series B: 75% of its rounds

  3. 03

    Sole investor in 4 rounds, median $12M

  4. 04

    2 exits from the portfolio

What they do

Filed 1 private fund offering with the SEC, the most recent in 2023-12From their own website
Type
VC firm (from a list, unverified)
Cheque size
$100K – $5.0M as they say
Stages
SeedSeries ASeries BGrowth
Sectors
AnalyticsBio TechnologyBiotechnology
Based in
Boston, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first53 appearances

  1. 2026

    6 rounds

  2. Aug
    Khartis TherapeuticsSeries B · US · Ventureburn$50MWith 5 others
  3. Apr
    NeomorphSeries B · US · TechStartups$100MWith 4 others
  4. Apr
    Sidewinder TherapeuticsSeries B · US · Ventureburn$137MWith 8 others
  5. Apr
    Coultreon BiopharmaSeries A · BE$125MWith 2 others
  6. Feb
    EvommuneUS$125MWith 5 others
  7. Jan
    Mediar TherapeuticsSeries B · US$76MWith 2 others
  8. 2025

    11 rounds

  9. Nov
    AAVantgarde BioSeries B · IT$141MWith 3 others
  10. Nov
    Verastem OncologyUS$90MWith 4 others
  11. Oct
    VerteroSeries D · US$20MWith 2 others
  12. Sept
    Avenzo TherapeuticsSeries B · US$60MWith 5 others
  13. Sept
    Crystalys TherapeuticsSeries A · US$205MWith 3 others
  14. Sept
    KalVista PharmaceuticalsDebt · US$125MWith 4 others
  15. Apr
    Solu TherapeuticsSeries A · US$41MWith 3 others
  16. Feb
    XyloCor TherapeuticsSeries B · US · Crunchbase News$68MWith 2 others
  17. Feb
    Newleos TherapeuticsSeries A · US$94MWith 3 others
  18. Jan
    Interius BioTherapeuticsVenture · US$22MWith 3 others
  19. Jan
    Be BiopharmaSeries C · US$92MWith 3 others
  20. 2024

    5 rounds

  21. Dec
    TScan TherapeuticsUS$30MWith 5 others
  22. Jun
    Interius BioTherapeuticsSeries B · US$51MWith 2 others
  23. May
    BbotVenture · US$200MWith 4 others
  24. May
    Progentos TherapeuticsSeries A · US$65MWith 2 others
  25. Mar
    Engrail TherapeuticsSeries B · US$157MWith 4 others
  26. 2023

    3 rounds

  27. Dec
    Tome BiosciencesSeries A · US$213MWith 4 others
  28. Dec
    Lassen TherapeuticsSeries B · US$85MWith 2 others
  29. Sept
    Sitryx TherapeuticsSeries A · GB$39MWith 4 others
  30. 2022

    6 rounds

  31. Dec
    PulmocideSeries C · GB$52MWith 3 others
  32. Sept
    Photys TherapeuticsSeries A · US$75MWith 2 others
  33. Jun
    Carbon BiosciencesSeries A · US$38MWith 3 others
  34. Jun
    DEM BioPharmaSeries A · US$70MWith 2 others
  35. May
    Werewolf TherapeuticsSecondary · US$50MWith 3 others
  36. Mar
    Calithera BiosciencesUS$10MWith 1 other
  37. 2021

    4 rounds

  38. Oct
    Rectify PharmaceuticalsSeries A · US$100MWith 3 others
  39. Aug
    Immunitas TherapeuticsSeries B · US$58MSole investor
  40. Jun
    ImmuneIDSeries A$50MWith 3 others
  41. Apr
    RenoviaSeries C$17MWith 3 others
  42. 2020

    1 round

  43. Mar
    Millendo Therapeutics$50MWith 3 others
  44. 2019

    5 rounds

  45. Dec
    ArcherDxSeries C · US · FinSMEs$55MWith 8 others
  46. Nov
    Wereworld TherapeuticsSeries A · US · FinSMEs$56MLed
  47. Jul
    Tscan TherapeuticsSeries B · US · FinSMEs$48MWith 4 others
  48. May
    ArcherDXSeries B · US · FinSMEs$60MWith 4 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration4 named

CWChristoph WestphalManaging Member of the General PartneriFiling they signed
DADavid A SteinbergOther Executive OfficeriForm ADV
JOJoshua O'Brien LubovChief Financial OfficeriForm ADV
RHRichard H. (mi Only) AldrichOther Executive OfficeriForm ADV

We also hold 15 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$456Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
Legal name
Longwood Management LLC
SEC number
CRD 281220

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

VerastemListed$52MJul 2013
PTC TherapeuticsListed$125MJun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Longwood Fund. A count of rooms they were both in, not a relationship either has claimed.

RA Capital ManagementPrivate equity8rounds togetherBessemer Venture PartnersVC firm7rounds togetherAlexandria Venture InvestmentsVC firm5rounds togetherMPM CapitalPrivate equity5rounds togetherCormorant Asset ManagementPrivate equity4rounds togetherForbion Capital PartnersPrivate equity4rounds togetherNovo HoldingsVC firm4rounds togetherSofinnova PartnersVC firm4rounds togetherARCH Venture PartnersVC firm3rounds togetherAdage Capital ManagementAsset manager3rounds togetherCardinal PartnersVC firm3rounds togetherDCVCVC firm3rounds together

Recently backed

The latest companies Longwood Fund put money into.

Sidewinder Therapeutics$137M · Apr 2026Coultreon Biopharma$125M · Apr 2026Evommune$125M · Feb 2026Mediar Therapeutics$76M · Jan 2026AAVantgarde Bio$141M · Nov 2025Verastem Oncology$90M · Nov 2025

Quick answers about Longwood Fund

What does Longwood Fund invest in?

Longwood Fund invests most often at Series A and Series B (75% of the rounds on record), in sectors such as Analytics, Bio Technology and Biotechnology.

How active is Longwood Fund?

53 investments on record, 8 of them in the last 12 months, and it led 1. The most recent was in Aug 2026.

What has Longwood Fund invested in recently?

Its most recent investments on record: Khartis Therapeutics (Series B, Aug 2026), Neomorph (Series B, Apr 2026) and Sidewinder Therapeutics (Series B, Apr 2026).

How big are Longwood Fund's cheques?

The median round it joins is $60M. It says it writes cheques of $100K to $5.0M.

Does Longwood Fund lead rounds?

Sometimes: it led 1 of its 53 investments on record (2%).

Where does Longwood Fund invest?

Most of the companies it backs are in the United States (89%) and the United Kingdom (5%).

Is Longwood Fund investing now?

Yes: it is actively investing, with 8 investments in the last 12 months.

Who does Longwood Fund invest alongside?

Most often RA Capital Management (8 rounds together), Bessemer Venture Partners (7 rounds together) and Alexandria Venture Investments (5 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it